CSV Program in Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas

ASPIRIN Data in the CSV software format.
Study Description
The purpose of this study was to learn whether a daily 81 mg dose of aspirin given to Nulliparas, beginning between 6-13 weeks of pregnancy, and continuing until 36 weeks of pregnancy, can reduce the risk of preterm birth. Nulliparous women appeared to be an ideal population since they will not undergo special interventions in an attempt to avoid preterm birth and are high risk pregnancies. The study design was a randomized, placebo-controlled, double-blinded multicenter clinical trial to assess the efficacy of Low Dose Aspirin (LDA) in the reduction of preterm birth. Women were randomized equally to receive either daily LDA (81 mg) or a placebo beginning between 6 0/7 weeks and 13 6/7 weeks Gestational Age (GA) and continued until 36 0/7 weeks GA or delivery. The primary outcome of this study was preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks determined by comparing actual delivery date to the projected Estimated Due Date (EDD). A total of 11,920 nulliparous women were enrolled (5960 per group) across seven sites in sub-Saharan Africa, South Asia, and Latin America. For balance, each site enrolled no more than 25% of the total sample.